Effects of long-term interferon-α treatment on glucose tolerance in patients with chronic hepatitis C

Ito, Yasufumi; Takeda, Noriyuki; Ishimori, Masatoshi; Akai, Akifumi; Miura, Kiyoshi; Yasuda, Keigo

doi:10.1016/s0168-8278(99)80216-5

Cited by 31 publications

(16 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Three months after completion of IFN-treatment, the prevalence declined to 12 and 20% respectively. The results were similar to those of previous reports (Ito et al 1999, Konrad et al 1999 and indicated a minor beneficial long-term effect of IFNtherapy on glucose homeostasis. Moreover, all except one of them had HCV infection, suggesting that HCV, rather than HBV, may play an important role in the development of diabetes mellitus.…”

Section: Discussionsupporting

confidence: 91%

“…Based on previous reports, we recommended that IFN-should still be used with caution in patients with a predisposition to autoimmune disease and diabetes mellitus. Although IFN-has been reported to induce acute insulin resistance in patients with chronic active HCV infection (Koivisto et al 1989, Ishigami et al 1994, Imano et al 1998, long-term IFN-treatment seems to produce no detrimental effect on insulin sensitivity and glucose tolerance (Ito et al 1999). One study even suggests that IFN-can improve glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease (Konrad et al 1999(Konrad et al , 2000.…”

Section: Insulin Sensitivity In Response To Ifn-· T-y Tai and Others 461mentioning

confidence: 99%

“…The effective amelioration rate of the liver function was about 30 and 40% respectively, in chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infections (Moriyama et al 1993, Poynard et al 1996. On the one hand IFN-has been reported to induce type 1 diabetes (Foulis et al 1987, Fabris et al 1992, Waguri et al 1994, Cesare et al 1996, Eibl et al 2001 and acute insulin resistance (Koivisto et al 1989, Ishigami et al 1994, Imano et al 1998 in patients with chronic HCV infection, and on the other hand some studies claim that long-term IFN-treatment for patients with HCV infection, instead of causing deterioration of insulin sensitivity and glucose tolerance, is capable of improving glucose tolerance (Ito et al 1999, Konrad et al 1999. In short, the role IFN-plays in glucose homeostasis for patients with HCV infection remains to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C

Lu²,

Cl³

et al. 2003

Journal of Endocrinology

View full text Add to dashboard Cite

This study aimed at elucidating the effects of interferon (IFN)-on glucose metabolism in patients with chronic hepatitis B and C infections. Twenty-eight biopsy-proven patients with chronic hepatitis B (ten cases) and hepatitis C (18 cases) were given IFN-for a total of 24 weeks. The patients received a 75 g oral glucose tolerance test (OGTT), glucagon stimulation test, tests for type 1 diabetes-related autoantibodies and an insulin suppression test before and after IFN-therapy. Ten of the 28 patients responded to IFN-therapy. Steady-state plasma glucose of the insulin suppression test decreased significantly in responders (13·32 1·48 (S.E.M.) vs 11·33 1·19 mmol/l, P=0·0501) but not in non-responders (12·29 1·24 vs 11·11 0·99 mmol/l, P=0·2110) immediately after completion of IFN-treatment. In the oral glucose tolerance test, no significant difference was observed in plasma glucose in either responders (10·17 0·23 vs 10·03 0·22 mmol/l) or non-responders (10·11 0·22 vs 9·97 0·21 mmol/l) 3 months after completion of IFNtreatment. However, significant differences were noted in C-peptide in both responders (2·90 0·13 vs 2·20 0·09 nmol/l, P=0·0040) and non-responders (2·45 0·11 vs 2·22 0·08 nmol/l, P=0·0287) before vs after treatment. The changes of C-peptide in an OGTT between responders and non-responders were also significantly different (P=0·0028), with responders reporting a greater reduction in C-peptide. No case developed autoantibodies during the treatment. In patients who were successfully treated with IFN-, insulin sensitivity improved and their plasma glucose stayed at the same level without secreting as much insulin from islet -cells.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Insulin Sensitivity In Response To Ifn-· T-y Tai and Others 461mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C

Lu²,

Cl³

et al. 2003

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Studies in nondiabetic patients report that interferon impairs glucose tolerance (161)(162)(163). A recent trial, however, failed to Type 2 diabetes and liver disease detect a difference in insulin sensitivity and glucose tolerance after 6 months of interferon treatment (164), while another study reported that fasting plasma glucose and fasting immunoreactive insulin decreased during interferon treatment (72). The practical implications of the observed changes in glucose homeostasis in patients being treated with interferon are not known.…”

Section: Treatment Of Nafldmentioning

confidence: 99%

Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease

et al. 2007

View full text Add to dashboard Cite

“…Classical IFN-α has been reported to induce insulin resistance [8][9][10][11] although there are also reports suggesting a beneficial effect on glucose metabolism [12][13][14] . However, the potential of classical IFN-α to induce IDDM has not been well established.…”

Section: Discussionmentioning

confidence: 99%

Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C

Soultati¹

2007

WJG

View full text Add to dashboard Cite

Classical interferon-alpha has been shown to be correlated with the development of a variety of autoimmune disorders. A 38 year-old female patient developed simultaneously diabetic ketoacidosis and hyperthyroidism 5 mo following initiation of treatment with pegylated interferon-α and ribavirin for chronic hepatitis C. High titers of glutamic acid decarboxylase, antinuclear and thyroid (thyroid peroxidase and thyroglobulin) antibodies were detected. Antiviral treatment was withdrawn and the patient was treated with insulin for insulin-dependent diabetes mellitus and propranolol for hyperthyroidism. Twelve months after cessation of pegylated interferon-α therapy the patient was euthyroid without any medication but remained insulin-dependent.

show abstract

Effects of long-term interferon-α treatment on glucose tolerance in patients with chronic hepatitis C

Cited by 31 publications

References 21 publications

Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C

Interferon-alpha reduces insulin resistance and beta-cell secretion in responders among patients with chronic hepatitis B and C

Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease

Simultaneous development of diabetic ketoacidosis and Hashitoxicosis in a patient treated with pegylated interferon-alpha for chronic hepatitis C

Contact Info

Product

Resources

About